[go: up one dir, main page]

NO20080433L - Luftveisadministrering av aktivt protein C i inflammatoriske tilstander som pavirker luftveiene - Google Patents

Luftveisadministrering av aktivt protein C i inflammatoriske tilstander som pavirker luftveiene

Info

Publication number
NO20080433L
NO20080433L NO20080433A NO20080433A NO20080433L NO 20080433 L NO20080433 L NO 20080433L NO 20080433 A NO20080433 A NO 20080433A NO 20080433 A NO20080433 A NO 20080433A NO 20080433 L NO20080433 L NO 20080433L
Authority
NO
Norway
Prior art keywords
respiratory tract
administration
inflammatory conditions
active protein
conditions affecting
Prior art date
Application number
NO20080433A
Other languages
English (en)
Inventor
Lars Otto Uttenthal
Original Assignee
Drugrecure Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drugrecure Aps filed Critical Drugrecure Aps
Publication of NO20080433L publication Critical patent/NO20080433L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Den foreliggende oppfinnelse tilveiebringer fremgangsmåter for lokal behandling av akutt og kronisk ekstravaskulær pulmonal fibrindeponering og/eller å redusere uønskede effekter assosiert med systemisk administrering av antikoagulanter til et individ via luftveisadministrering til individet ved intratrakeale, intrabronkiale eller intraalveolære ruter av antikoagulanter eller biologisk aktive derivater derav.
NO20080433A 2005-06-24 2008-01-23 Luftveisadministrering av aktivt protein C i inflammatoriske tilstander som pavirker luftveiene NO20080433L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69396805P 2005-06-24 2005-06-24
PCT/IB2006/002773 WO2007012976A2 (en) 2005-06-24 2006-06-23 Airway administration of activated protein c in inflammatory conditions affecting the respiratory tract

Publications (1)

Publication Number Publication Date
NO20080433L true NO20080433L (no) 2008-03-19

Family

ID=37570814

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20080433A NO20080433L (no) 2005-06-24 2008-01-23 Luftveisadministrering av aktivt protein C i inflammatoriske tilstander som pavirker luftveiene
NO20080434A NO20080434L (no) 2005-06-24 2008-01-23 Luftveisadministrering av vevsfaktor veiinhibitorer i inflammatoriske tilstander som pavirker luftveien

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20080434A NO20080434L (no) 2005-06-24 2008-01-23 Luftveisadministrering av vevsfaktor veiinhibitorer i inflammatoriske tilstander som pavirker luftveien

Country Status (14)

Country Link
US (3) US20100279925A1 (no)
EP (3) EP1896059B1 (no)
JP (3) JP2008543926A (no)
KR (2) KR20080071116A (no)
CN (2) CN101262880A (no)
AU (2) AU2006260599A1 (no)
BR (2) BRPI0611710A2 (no)
CA (2) CA2612597C (no)
DK (3) DK1906994T3 (no)
IL (2) IL188221A0 (no)
NO (2) NO20080433L (no)
RU (2) RU2496516C2 (no)
WO (3) WO2007012976A2 (no)
ZA (2) ZA200800251B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010512350A (ja) * 2006-12-11 2010-04-22 ダラグレキュル・アンパルトセルスカブ ホスホマイシンの肺投与により細菌感染を伴う嚢胞性線維症または肺炎を処置するための方法
CN104394883B (zh) 2012-07-04 2017-05-31 悉尼大学 炎性皮肤病症的治疗
EP3137102B1 (en) * 2014-04-16 2021-07-14 ZZ Biotech LLC Apc for use in the treatment of abnormal cutaneous scarring
US20170035862A1 (en) 2014-04-16 2017-02-09 Zz Biotech Llc Use of APC analogue for wound healing
EP3512539A4 (en) * 2016-09-13 2020-07-29 Prothera Biologics, Inc. METHODS FOR TREATING LUNG DISEASE USING INTER-ALPHA INHIBITOR PROTEINS

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US4966852A (en) * 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US6013619A (en) * 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
DK408089D0 (da) * 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
US5378614A (en) * 1989-08-18 1995-01-03 Novo Nordisk A/S Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
SE9200541D0 (sv) * 1992-02-24 1992-02-24 Kabi Pharmacia Ab New usee of omega-3-fatty acids
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
DE69735597T2 (de) * 1996-11-08 2006-12-21 Oklahoma Medical Research Foundation, Oklahoma Verwendung eines modifizierten protein-c
CA2278823A1 (en) * 1997-01-29 1998-07-30 Joe M. Mccord Plasminogen activator as an anti-inflammatory agent
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6049577A (en) * 1998-05-28 2000-04-11 Glenayre Electronics, Inc. Header synchronization detector
AR023819A1 (es) * 1999-05-03 2002-09-04 Astrazeneca Ab FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION
JP4848092B2 (ja) * 2000-02-01 2011-12-28 石原産業株式会社 ジアミノトリフルオロメチルピリジン誘導体を含有する肺不全の治療剤又は予防剤
EP1255821B1 (en) * 2000-02-02 2004-12-29 Eli Lilly And Company Protein c derivatives
WO2001058935A2 (en) * 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
US6933367B2 (en) * 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
KR20040094288A (ko) * 2001-05-02 2004-11-09 노보 노르디스크 에이/에스 Ａｒｄｓ의 치료에 있어 변형된 ｆⅶ
DE10132307A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
EA200400549A1 (ru) * 2001-10-15 2005-02-24 Чирон Корпорейшн Лечение сепсиса введением малых доз ингибитора пути тканевого фактора (tfpi)
JP4229840B2 (ja) * 2002-02-08 2009-02-25 エスケー エナジー 株式会社 ヒーターチューブの洗浄のための洗浄剤および方法
AU2003223718B2 (en) * 2002-04-25 2007-08-16 The Scripps Research Institute Treatment and prevention of pulmonary conditions
WO2004062689A1 (en) 2003-01-08 2004-07-29 Chiron Corporation Stabilized aqueous compositions comprising tissue factor pathway inhibitor (tfpi) or tissue factor pathway inhibitor variant
JPWO2004087148A1 (ja) * 2003-03-31 2006-06-29 協和醗酵工業株式会社 肺疾患の治療および／または予防剤
WO2005042011A1 (en) * 2003-11-04 2005-05-12 Novo Nordisk A/S Pharmaceutical composition comprising a protein c polypeptide and a blood glucose regulator
KR101241434B1 (ko) * 2004-09-10 2013-03-12 파마오리진 에이피에스 국소 기관, 기관지 또는 폐포의 출혈 또는 객혈의 치료방법
CA2582353A1 (en) 2004-10-06 2006-04-20 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway

Also Published As

Publication number Publication date
WO2006136962A2 (en) 2006-12-28
HK1114567A1 (en) 2008-11-07
EP1898945B1 (en) 2012-12-19
AU2006273696A1 (en) 2007-02-01
WO2007012976A2 (en) 2007-02-01
EP1906994B1 (en) 2014-04-23
AU2006260599A1 (en) 2006-12-28
US20100160218A1 (en) 2010-06-24
CN101262879A (zh) 2008-09-10
DK1906994T3 (da) 2014-07-21
RU2496516C2 (ru) 2013-10-27
WO2006136962A3 (en) 2007-07-12
EP1896059B1 (en) 2012-12-19
DK1898945T3 (da) 2013-03-25
CA2612646C (en) 2015-11-24
NO20080434L (no) 2008-03-17
US8088728B2 (en) 2012-01-03
WO2007012976A3 (en) 2007-07-12
US20100297099A1 (en) 2010-11-25
RU2008102655A (ru) 2009-07-27
JP2008543925A (ja) 2008-12-04
RU2008102656A (ru) 2009-07-27
BRPI0613137A2 (pt) 2010-12-21
JP2008543926A (ja) 2008-12-04
EP1898945A2 (en) 2008-03-19
ZA200800251B (en) 2009-04-29
DK1896059T3 (da) 2013-04-08
JP2013151510A (ja) 2013-08-08
ZA200800255B (en) 2009-04-29
CA2612597C (en) 2015-03-31
CN101262880A (zh) 2008-09-10
EP1896059A2 (en) 2008-03-12
RU2496515C2 (ru) 2013-10-27
WO2006136963A2 (en) 2006-12-28
IL188221A0 (en) 2008-03-20
BRPI0611710A2 (pt) 2011-12-20
WO2006136963A3 (en) 2007-07-12
US20100279925A1 (en) 2010-11-04
KR20080074085A (ko) 2008-08-12
CN101262879B (zh) 2013-04-10
AU2006273696B2 (en) 2012-08-30
KR20080071116A (ko) 2008-08-01
IL188220A0 (en) 2008-03-20
CA2612597A1 (en) 2007-02-01
CA2612646A1 (en) 2006-12-28
EP1906994A2 (en) 2008-04-09

Similar Documents

Publication Publication Date Title
NO20080433L (no) Luftveisadministrering av aktivt protein C i inflammatoriske tilstander som pavirker luftveiene
Porteous et al. Primary graft dysfunction: lessons learned about the first 72 h after lung transplantation
Matalon et al. Role of epithelial sodium channels in the regulation of lung fluid homeostasis
Prabhakaran et al. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury
Chignalia et al. The glycocalyx and trauma: a review
Butterfield The Power of Anacrusis
Wösten-van Asperen et al. ACE mediates ventilator-induced lung injury in rats via angiotensin II but not bradykinin
NO20065232L (no) 8-(2-hydroksyfenoksy)oktyldietanolamin og salter derav for avlevering av aktive forbindelser
WO2015016761A3 (en) Mscs in the treatment of inflammatory pulmonary diseases
NO20072466L (no) Fremgangsmate for a forhindre og behandle strukturendring i luftveier og pulmonal inflammasjon ved a anvende A2B-adenosinreseptorantagonister
ATE516285T1 (de) Dihydropyridinonderivate
DK1874341T3 (da) Erythrocytter, der indeholder arginin deiminase
NO20070987L (no) Polysulfaterte glykosider og salter av disse.
Pilecki et al. Surfactant protein D deficiency aggravates cigarette smoke-induced lung inflammation by upregulation of ceramide synthesis
ATE525394T1 (de) Peptide mit verbesserten eigenschaften mit der biologischen wirkung eines vasoaktiven intestinalen peptids (vip) und ihre verwendung zur behandlung von lungenerkrankung
PH12012500826A1 (en) Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists
FI20070937A7 (fi) Perhekeinu
Mohammad et al. Variceal bleeding in cirrhotic patients: What is the best prognostic score
Lau et al. Enhanced fibrinolysis protects against lung ischemia–reperfusion injury
Deravi et al. Complement inhibition: a possible therapeutic approach in the fight against Covid‐19
EP2322646A8 (en) Method of detecting platelet thrombosis or organ failure
Hussein et al. The Impact of Cigarette Smoking on Clinical Progress of COVID-19 in Hospitalized Patients at Al-Kindey Teaching Hospital, Baghdad, Iraq
JP2009520696A5 (no)
Hiraishi et al. Development of papain-induced asthma-COPD overlap mice model
ATE431755T1 (de) Filternder abscheider für partikelbelastete gase